Solvay Pharmaceuticals
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Solvay Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#473 of 15,742 sponsors by registered trial count).
Solvay Pharmaceuticals: 35 sponsored US clinical trials, none currently recruiting.
Solvay Pharmaceuticals sponsors 35 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 29 completed. 19 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, with 1 trials.
Top-decile sponsor footprint
Solvay Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#473 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
29 of 35 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
35 total, page 1 of 1
Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure
NCT00998933
Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
NCT00775528
Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure
NCT00744341
Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)
NCT00690820
Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
NCT00510484
A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy
NCT00414908
Study to Evaluate the Effect of SLV320 in Addition to Chronic Furosemide Treatment on Renal Function in Subjects With Congestive Heart Failure and Impaired Renal Function
NCT00568009
An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
NCT00335374
An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.
NCT00407095
Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients
NCT00396214
SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations
NCT00406588
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
NCT00332917
Switch Study of Existing Atypical Antipsychotics to Bifeprunox
NCT00347425
SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
NCT00335166
SLV308 for Treatment of Patients With Early Parkinson's Disease
NCT00269516
Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder
NCT00139919
Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
NCT00160147
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
NCT00123201
Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia
NCT00139906
Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes
NCT00160342
To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox
NCT00141479
PK Effects of Bifeprunox & Valproate in Bipolar I
NCT00141505
Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects
NCT00126022
Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion
NCT00160199
Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Male Subjects
NCT00126061
Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes
NCT00141492
Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects
NCT00126074
The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women
NCT00141557
The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women
NCT00141544
Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women
NCT00141570
Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting
NCT00642499
Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting
NCT00642512
Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism
NCT00193661
Pharmacokinetic Evaluation of Testosterone Gel (1%)
NCT00193700
Efficacy of Pancrelipase on Postprandial Belching and Bloating.
NCT00266721
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 13 |
| Phase 3 | 18 |
| Phase 4 | 1 |
How the Solvay Pharmaceuticals archive is shaped
35 indexed studies, none listed as recruiting (0% open); 29 completed (83%).
Phase mix: 19 late (III/IV) vs 15 early (I/II) (balanced across stages).
Top condition: Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting (1 trial), 6 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Solvay Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 35 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Solvay Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 35 archived trials
- ACADIA Pharmaceuticals · 35 trials · 9% recruiting
- INSYS Therapeutics · 35 trials · 0% recruiting
- Merz North America · 35 trials · 3% recruiting
- Palo Alto Veterans Institute for Research · 35 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Solvay Pharmaceuticals page
35 registered trials is a research-attention snapshot, not an endorsement of Solvay Pharmaceuticals or any single study.
- None of Solvay Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting is the condition Solvay Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Solvay Pharmaceuticals pipeline card: 35 registered trials from official public datasets.Report a data error.